THE INNOVATION OF ESTEVE IS RECOGNIZED AGAIN AS EXCELLENT BY PROFARMA
Esteve has been rated again as "Excellent" in terms of R&D by the Profarma Plan of the Ministry of Industry. This recognition is the 30th that the company has received uninterrupted since Profarma began these evaluations in 1986.
The Profarma Plan (2013-2016) places ESTEVE in Group A (Excellent), a classification that recognizes the success of truly innovative pharmaceuticals which clearly bets on research with its own pharmaceutical plant or own R&D center. In this way, ESTEVE reaches the highest score among the more than 50 companies in the sector that Profarma analyzes.
Profarma is a call that unites the will of the Minister of Industry, Energy and Tourism; Economy and Competitiveness and Health, Social Services and Equality, to promote the competitiveness of the Pharmaceutical Industry with the approval of the Delegated Commission of the Government for Economic Affairs. Its main goal is to stimulate the competitiveness of the sector through the modernization of its companies and to support the activities with greater added value.
Innovation has been the driving force behind ESTEVE and its growth since its beginnings in 1929. Today, it works with a portfolio of innovative projects that seek to provide solutions to medical needs not adequately covered and with a great social impact.
You can follow ESTEVE on Twitter: twitter.com/esteve_news.
THE PROGRAM ’PLAN PROFARMA’ HAS ONCE AGAIN QUALIFIED ESTEVE’S R&D&I AS ’’EXCELLENT’’
Once again, ESTEVE's research activity has received the qualification ''Excellent'' in the Program 'Plan Profarma' (Program for Fostering Scientific Research, Technological Development and Innovation ...read more
PENSA PHARMA HAS BEEN AWARDED A PRIZE FOR ITS BEST DEVELOPMENT AND COMMERCIALIZATION OF GENERIC MEDICINES
Pensa Pharma (PENSA), a company of the ESTEVE Group specialized in generic medicines, has been awarded a prize at the II edition of La Razón Comunidad Valenciana Awards. Specifically, PENSA has receiv...read more
ESTEVE APPOINTS THOMAS B. RIISAGER AS CHIEF CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICER
ESTEVE has announced today the appointment of Thomas B Riisager as Chief Corporate Strategy & Business Development Officer, to be heading Corporate Strategy & Business Development for the pharmaceutic...read more